Behind The Bribery Scandal In The Pharmaceutical Industry, The Sale Of "Cancer" Is Going To Be Cleared.

Recently, Heng Rui medicine once again caught in bribery. Lei Lipei, director of the Department of Anesthesiology of Lishui Central Hospital in Zhejiang Province, was sentenced to 7 years' imprisonment for accepting bribes. He was one of the main bribes in this case. He repeatedly bribed Lei Lipei for a total of nearly 2 million 770 thousand yuan.

Public information shows that Heng Rui medicine has been involved in bribery many times. And the pharmaceutical industry is also frequent commercial bribery incidents, including Fosun medicine, Huarun 39, step pharmaceutical, sea king group and many other pharmaceutical companies. Shi Lichen, head of Beijing Ding Chen medical management center, told the twenty-first Century economic analysis reporter that the commercial bribe was actually decided by the past medicine industry's "gold sales" mode, which belongs to the historical depression. The reality of national collection is to cut off the gray interests chain.

"The state has paid a lot of attention to the sale of gold, but in the past, dealers and bribe doctors were not punished. Now we are more concerned about how to bear the responsibility of the bribe owners in the future. This is also the key to better remove this malformed tumor. An industry veteran told the economic news reporters in twenty-first Century.

Hang Rui medicine retreats corruption

China's referee's official website shows that between 2016 and 2019, the sales representative of Jiangsu new morning Pharmaceutical Co., Ltd., the sales representative of Hsing Rui Pharmaceutical Co., Ltd., Sun Mou, the regional manager of Zhejiang Province and the manager of Zhejiang Jiangxi region, gave Lei Lipei 200 thousand yuan, 200 thousand yuan and 8 thousand yuan respectively.

From February 2017 to June 2019, 5 new drugs sold by the new morning medicine were used in the anesthesiology department of Lishui Central Hospital. The sales representatives of the new morning pharmaceutical company Xu and ye gave Lei Lipei a rebate of 2 million 360 thousand yuan. After receiving Lei Lipei, some of the kickbacks were handed over to the anesthesiology department, and the rest was owned by individuals.

In addition to Lei Li Pei's bribery, a verdict issued by China's referee network in January 2020 showed that Xin Chen had bribed Lian Qingquan, the Second Affiliated Hospital of Wenzhou Medical University, Yuying children's Hospital and the second clinical medical college, to bribe over 470 thousand yuan.

According to public information, in recent years, Heng Rui medicine has been involved in bribery many times, widely distributed in Jiangsu, Fujian, Guangxi, Shaanxi and other provinces and cities. For example, from 2013 to 2014, Xia Moujia, director of the Department of Radiology, Kaihua People's Hospital, director of the Department of radiology of Zhengzhou, has paid 33 thousand yuan in cash, and Zhao, director of the third office of Zhengzhou Medical Marketing Co., Ltd., bribes 60 thousand yuan to the director of the Department of pharmacy.

From July 2012 to July 2014, the CT magnetic resonance room of Fuyang People's Hospital used 3230 doses of iodophor and 4860 iodized alcohol. The deputy director of the CT room of the hospital, a butcher, received many kickbacks from the medical company of Heng Rui for a total of 387 thousand and 900 yuan.

In the same period with Lei Lipei, he was also the director, director and doctor of the first people's Hospital of Laishan District of Yantai and Langfang Hospital of Anci district. The bribery parties involved include Harbin Pharmaceutical Group, Tiansheng pharmaceuticals, longevity bio, Kangmei pharmaceutical, Watson biology, Liupanshui Jisheng pharmaceutical industry, Novartis pharmaceuticals, modified pharmaceutical industry, and many other well-known pharmaceutical companies.

A listed pharmaceutical company responsible person told the twenty-first Century economic news reporter that many business models were "selling with gold", so in the past, the Chinese pharmaceutical industry was mainly guided by sales, with little innovation and huge investment in sales.

According to Wind data, according to Shen Wan industry classification, in 2019, Shanghai medicine became a A share pharmaceutical and biological industry with "12 billion 856 million yuan sales cost" as the highest cost of selling medical expenses. After that, Fosun medicine followed closely. In 2019, the sales cost was directly billion billion, reaching 9 billion 847 million yuan; in addition, another 70 sales expenses exceeded 1 billion yuan.

As mentioned above, 2019 annual report shows that there are 14686 sales staff in Heng Rui medicine, the annual sales cost is 8 billion 500 million yuan, the sales revenue of tumor drugs is 43.02% higher than that of last year, and the sales revenue of imaging products increased by 38.97% over last year.

Also, such as step pharmaceutical, sales costs in the first quarter of 2020 were as high as 1 billion 390 million yuan, with an average daily expenditure of more than 15 million yuan, accounting for 52.65% of the first quarter revenue. In 2019, the annual report showed that the sales cost of pharmaceutical sales reached 8 billion 80 million yuan, an increase of 0.56% over the previous year. Among them, 7 billion 649 million yuan was listed as a market, academic promotion fee and consulting fee, accounting for 94%.

"Tumor" to be cleared

In fact, after the two vote system, most of the pharmaceutical companies' sales expenses increased even further. According to incomplete statistics, only in the first 5 months of 2019, there were 16 listed pharmaceutical companies who had received excessive inquiries and regulatory letters from the regulatory authorities due to excessive growth in sales expenses or even faster than the growth of revenue. They asked for the reasonableness of the growth of sales expenses, and eventually attracted the heavy punches of regulators.

In 2019, the Ministry of finance also conducted a special inspection of the sales expenses of pharmaceutical companies. Among them, the inspection focused on whether there was a large amount of cash in all kinds of invoices, such as consulting fees, meeting fees, accommodation fees, transportation fees and so on; whether the expenses of meeting fees were true or not, and whether the contents of invoice were consistent with the schedule of meetings, participants, meeting places, etc.

For a long time, the pharmaceutical industry has been a serious area of corruption, and bribery has been repeatedly banned. "Sales oriented, we can not avoid the gold sales model. Now the state procurement form has directly cut off the chain of interests, restructured the sales market pattern of generic products, with the volume of procurement, the price of winning products will decline sharply, the price decline means that the cost is strictly controlled, in fact, it is squeezing gold sales from the source. Shi Lichen said.

In fact, relevant departments have been cracking down on selling gold and cracking down on corruption in the medical industry. In 2018, the nine ministries and commissions such as the national Wei Jian Commission and the state health insurance bureau jointly issued the key points of special rectification work for correcting unhealthy practices in the field of medical purchase and sale in 2018 and then in medical services. Subsequently, provinces and cities issued documents on drug purchase and sale in succession, and the anti-corruption efforts gradually increased.

Wang Ying, CEO, told reporters in an interview with the economic news reporters in twenty-first Century that the newly revised Drug Administration Law also increased the prohibition of commercial bribery. In the list of administrative enforcement of the National Health Insurance Bureau in 2020, there were also related matters related to the commercial bribery inspection.

Not long ago, the National Health Insurance Bureau solicited the guidance on the establishment of drug price and recruitment credit evaluation system (Draft). It also showed that the National Health Insurance Bureau will make rational use of relevant departments to crack down on and deal with commercial bribery in the medical field, manipulate market law enforcement results, and take appropriate disciplinary measures to break faith through corporate commitment and contract management.

Among them, pharmaceutical companies are committed to eradicate commercial bribery and manipulate market behavior. They also commit themselves to undertake illegal actions such as commercial bribery and market manipulation, which are entrusted to service enterprises and agents.

"Accountable to pharmaceutical companies, as a" source of bribery "need to be responsible, rather than just business personnel, dealers, bribes doctors and other punished, pharmaceutical companies should also be responsible for sales personnel behavior. This will also better curb the sale of gold. The industry insiders said that the industry is concerned about the bribery incident of Heng Rui pharmaceutical company, which is representative of leading enterprises.